# AI指示糖尿病患者在碘造影剂给药期间及之后继续服用二甲双胍，未检查肾功能

- **ID:** `medical/contrast-hold-metformin`
- **领域:** medical
- **类别:** data_error
- **错误码:** `ACR-2024-MET`
- **验证级别:** ai_generated
- **修复率:** 82%

## 根因

碘造影剂可导致造影剂肾病（CIN），降低二甲双胍的肾脏清除率，诱发乳酸性酸中毒——一种罕见但致命的并发症。指南（ACR、ESUR）要求造影前检查eGFR；若eGFR<30 mL/min/1.73m²，需在造影前后各停用二甲双胍48小时；若eGFR 30-60，造影当日及之后48小时停用。

## 解决方案

1. ```
   Check eGFR before contrast. If eGFR >60 mL/min/1.73m²: continue metformin normally. If eGFR 30-60: hold metformin on day of contrast and for 48h after, then recheck eGFR. If eGFR <30: hold metformin 48h before and 48h after contrast, recheck eGFR before resuming.
   ```
2. ```
   For emergency contrast where pre-procedure eGFR is unavailable, hold metformin immediately, administer contrast, and check eGFR post-procedure. Resume metformin only if eGFR >30 and no evidence of CIN (creatinine rise <0.3 mg/dL).
   ```

## 无效尝试

- **Assuming all diabetic patients on metformin need to stop before contrast regardless of renal function** — Overly cautious; patients with normal renal function (eGFR >60) can continue metformin safely. The decision depends on eGFR. (50% 失败率)
- **Telling patient to resume metformin immediately after contrast without checking post-procedure renal function** — If CIN develops, the reduced eGFR may still put the patient at risk; guidelines recommend waiting 48h and confirming renal function stable before resuming. (75% 失败率)
- **Using BUN or creatinine alone without calculating eGFR** — Creatinine alone is misleading in elderly or low muscle mass patients; eGFR (CKD-EPI equation) is the standard for metformin dosing decisions. (65% 失败率)